nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—CA7—colon cancer	0.771	1	CbGaD
Methazolamide—CA14—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0149	0.12	CbGpPWpGaD
Methazolamide—CA5A—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0145	0.117	CbGpPWpGaD
Methazolamide—CA6—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0145	0.117	CbGpPWpGaD
Methazolamide—CA5B—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0135	0.109	CbGpPWpGaD
Methazolamide—CA12—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0125	0.101	CbGpPWpGaD
Methazolamide—CA4—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00998	0.0808	CbGpPWpGaD
Methazolamide—CYP2C9—Capecitabine—colon cancer	0.00965	0.336	CbGbCtD
Methazolamide—CA2—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00957	0.0775	CbGpPWpGaD
Methazolamide—CA1—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00918	0.0743	CbGpPWpGaD
Methazolamide—CA9—Reversible hydration of carbon dioxide—CA7—colon cancer	0.00807	0.0653	CbGpPWpGaD
Methazolamide—Acetazolamide—CA7—colon cancer	0.00724	1	CrCbGaD
Methazolamide—SLC22A6—Methotrexate—colon cancer	0.00687	0.239	CbGbCtD
Methazolamide—CYP2C9—Fluorouracil—colon cancer	0.00572	0.199	CbGbCtD
Methazolamide—CYP3A4—Irinotecan—colon cancer	0.00347	0.121	CbGbCtD
Methazolamide—CYP3A4—Vincristine—colon cancer	0.00303	0.105	CbGbCtD
Methazolamide—Hepatic insufficiency—Methotrexate—colon cancer	0.00271	0.0572	CcSEcCtD
Methazolamide—CA9—gall bladder—colon cancer	0.00224	0.102	CbGeAlD
Methazolamide—Electrolyte imbalance—Irinotecan—colon cancer	0.00202	0.0425	CcSEcCtD
Methazolamide—Bone marrow depression—Vincristine—colon cancer	0.00128	0.027	CcSEcCtD
Methazolamide—CA7—renal system—colon cancer	0.00122	0.0559	CbGeAlD
Methazolamide—CA5A—liver—colon cancer	0.00112	0.0513	CbGeAlD
Methazolamide—Tingling sensation—Fluorouracil—colon cancer	0.001	0.0212	CcSEcCtD
Methazolamide—CA7—digestive system—colon cancer	0.001	0.0458	CbGeAlD
Methazolamide—CA9—digestive system—colon cancer	0.00088	0.0403	CbGeAlD
Methazolamide—CA2—gall bladder—colon cancer	0.00085	0.0389	CbGeAlD
Methazolamide—Appetite absent—Methotrexate—colon cancer	0.000844	0.0178	CcSEcCtD
Methazolamide—Bone marrow depression—Capecitabine—colon cancer	0.000835	0.0176	CcSEcCtD
Methazolamide—CA12—renal system—colon cancer	0.000794	0.0363	CbGeAlD
Methazolamide—Urine output increased—Vincristine—colon cancer	0.000782	0.0165	CcSEcCtD
Methazolamide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—EP300—colon cancer	0.00074	0.00599	CbGpPWpGaD
Methazolamide—Polyuria—Vincristine—colon cancer	0.000715	0.0151	CcSEcCtD
Methazolamide—Tingling sensation—Capecitabine—colon cancer	0.000702	0.0148	CcSEcCtD
Methazolamide—CA9—Regulation of gene expression by Hypoxia-inducible Factor—VEGFA—colon cancer	0.000701	0.00567	CbGpPWpGaD
Methazolamide—Hepatic failure—Vincristine—colon cancer	0.000699	0.0147	CcSEcCtD
Methazolamide—Photosensitivity—Fluorouracil—colon cancer	0.000667	0.0141	CcSEcCtD
Methazolamide—CA12—digestive system—colon cancer	0.000651	0.0298	CbGeAlD
Methazolamide—CA1—renal system—colon cancer	0.000629	0.0288	CbGeAlD
Methazolamide—CA14—liver—colon cancer	0.000622	0.0285	CbGeAlD
Methazolamide—Bone marrow depression—Methotrexate—colon cancer	0.000622	0.0131	CcSEcCtD
Methazolamide—Melaena—Capecitabine—colon cancer	0.000551	0.0116	CcSEcCtD
Methazolamide—CA2—embryo—colon cancer	0.000539	0.0246	CbGeAlD
Methazolamide—CA9—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.000529	0.00428	CbGpPWpGaD
Methazolamide—CA1—lymphoid tissue—colon cancer	0.000522	0.0239	CbGeAlD
Methazolamide—CA1—digestive system—colon cancer	0.000516	0.0236	CbGeAlD
Methazolamide—CA5B—vagina—colon cancer	0.000516	0.0236	CbGeAlD
Methazolamide—Pancytopenia—Vincristine—colon cancer	0.000516	0.0109	CcSEcCtD
Methazolamide—Urine output increased—Capecitabine—colon cancer	0.00051	0.0107	CcSEcCtD
Methazolamide—Photosensitivity reaction—Vincristine—colon cancer	0.000496	0.0104	CcSEcCtD
Methazolamide—CA4—renal system—colon cancer	0.000492	0.0225	CbGeAlD
Methazolamide—Pancytopenia—Fluorouracil—colon cancer	0.000481	0.0101	CcSEcCtD
Methazolamide—CA1—bone marrow—colon cancer	0.000476	0.0217	CbGeAlD
Methazolamide—Polyuria—Capecitabine—colon cancer	0.000466	0.00982	CcSEcCtD
Methazolamide—Photosensitivity—Capecitabine—colon cancer	0.000466	0.00982	CcSEcCtD
Methazolamide—Photosensitivity reaction—Fluorouracil—colon cancer	0.000462	0.00974	CcSEcCtD
Methazolamide—CYP2D6—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.00046	0.00372	CbGpPWpGaD
Methazolamide—Hepatic failure—Capecitabine—colon cancer	0.000456	0.0096	CcSEcCtD
Methazolamide—Haemolytic anaemia—Capecitabine—colon cancer	0.000454	0.00955	CcSEcCtD
Methazolamide—CYP2E1—Metapathway biotransformation—CHST4—colon cancer	0.000453	0.00366	CbGpPWpGaD
Methazolamide—CA2—epithelium—colon cancer	0.00044	0.0201	CbGeAlD
Methazolamide—CA2—smooth muscle tissue—colon cancer	0.000423	0.0194	CbGeAlD
Methazolamide—Agranulocytosis—Fluorouracil—colon cancer	0.000421	0.00888	CcSEcCtD
Methazolamide—Melaena—Methotrexate—colon cancer	0.00041	0.00864	CcSEcCtD
Methazolamide—CA2—renal system—colon cancer	0.000408	0.0186	CbGeAlD
Methazolamide—CA4—digestive system—colon cancer	0.000403	0.0184	CbGeAlD
Methazolamide—Aplastic anaemia—Methotrexate—colon cancer	0.000394	0.0083	CcSEcCtD
Methazolamide—CA1—liver—colon cancer	0.000384	0.0176	CbGeAlD
Methazolamide—Urine output increased—Methotrexate—colon cancer	0.00038	0.008	CcSEcCtD
Methazolamide—CA4—bone marrow—colon cancer	0.000372	0.017	CbGeAlD
Methazolamide—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.000369	0.00777	CcSEcCtD
Methazolamide—CYP2C19—digestive system—colon cancer	0.000365	0.0167	CbGeAlD
Methazolamide—CYP2C19—Metapathway biotransformation—CHST4—colon cancer	0.000349	0.00283	CbGpPWpGaD
Methazolamide—Photosensitivity—Methotrexate—colon cancer	0.000347	0.00731	CcSEcCtD
Methazolamide—Polyuria—Methotrexate—colon cancer	0.000347	0.00731	CcSEcCtD
Methazolamide—Ill-defined disorder—Irinotecan—colon cancer	0.000342	0.0072	CcSEcCtD
Methazolamide—Vertigo—Vincristine—colon cancer	0.00034	0.00716	CcSEcCtD
Methazolamide—Hepatic failure—Methotrexate—colon cancer	0.000339	0.00714	CcSEcCtD
Methazolamide—Leukopenia—Vincristine—colon cancer	0.000339	0.00713	CcSEcCtD
Methazolamide—CA2—lymphoid tissue—colon cancer	0.000339	0.0155	CbGeAlD
Methazolamide—Pancytopenia—Capecitabine—colon cancer	0.000336	0.00708	CcSEcCtD
Methazolamide—CA2—digestive system—colon cancer	0.000334	0.0153	CbGeAlD
Methazolamide—CA5B—lymph node—colon cancer	0.000334	0.0153	CbGeAlD
Methazolamide—Malaise—Irinotecan—colon cancer	0.000332	0.007	CcSEcCtD
Methazolamide—Vertigo—Irinotecan—colon cancer	0.000331	0.00697	CcSEcCtD
Methazolamide—CA9—HIF-1-alpha transcription factor network—ABCB1—colon cancer	0.00033	0.00267	CbGpPWpGaD
Methazolamide—Leukopenia—Irinotecan—colon cancer	0.00033	0.00695	CcSEcCtD
Methazolamide—Convulsion—Vincristine—colon cancer	0.000328	0.0069	CcSEcCtD
Methazolamide—CYP2E1—renal system—colon cancer	0.000327	0.0149	CbGeAlD
Methazolamide—CA9—Cellular response to hypoxia—EP300—colon cancer	0.000327	0.00265	CbGpPWpGaD
Methazolamide—Photosensitivity reaction—Capecitabine—colon cancer	0.000323	0.0068	CcSEcCtD
Methazolamide—CYP2C19—vagina—colon cancer	0.000322	0.0147	CbGeAlD
Methazolamide—CYP2D6—Metapathway biotransformation—CHST4—colon cancer	0.000321	0.0026	CbGpPWpGaD
Methazolamide—CYP2C9—Metapathway biotransformation—CHST4—colon cancer	0.000318	0.00258	CbGpPWpGaD
Methazolamide—Leukopenia—Fluorouracil—colon cancer	0.000316	0.00665	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000313	0.00659	CcSEcCtD
Methazolamide—Discomfort—Irinotecan—colon cancer	0.00031	0.00653	CcSEcCtD
Methazolamide—CA9—Cellular response to hypoxia—VEGFA—colon cancer	0.00031	0.00251	CbGpPWpGaD
Methazolamide—Anaphylactic shock—Vincristine—colon cancer	0.000309	0.0065	CcSEcCtD
Methazolamide—CA2—bone marrow—colon cancer	0.000308	0.0141	CbGeAlD
Methazolamide—Convulsion—Fluorouracil—colon cancer	0.000306	0.00644	CcSEcCtD
Methazolamide—Confusional state—Irinotecan—colon cancer	0.000303	0.00639	CcSEcCtD
Methazolamide—CA14—Metabolism—CA7—colon cancer	0.000302	0.00244	CbGpPWpGaD
Methazolamide—Haematuria—Capecitabine—colon cancer	0.000301	0.00634	CcSEcCtD
Methazolamide—CYP3A4—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.000301	0.00243	CbGpPWpGaD
Methazolamide—Anaphylactic shock—Irinotecan—colon cancer	0.000301	0.00633	CcSEcCtD
Methazolamide—Discomfort—Fluorouracil—colon cancer	0.000297	0.00625	CcSEcCtD
Methazolamide—CA2—vagina—colon cancer	0.000295	0.0135	CbGeAlD
Methazolamide—CA1—lymph node—colon cancer	0.000295	0.0135	CbGeAlD
Methazolamide—Agranulocytosis—Capecitabine—colon cancer	0.000294	0.0062	CcSEcCtD
Methazolamide—Anorexia—Vincristine—colon cancer	0.000294	0.0062	CcSEcCtD
Methazolamide—CA6—Metabolism—CA7—colon cancer	0.000294	0.00238	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—CA7—colon cancer	0.000294	0.00238	CbGpPWpGaD
Methazolamide—Confusional state—Fluorouracil—colon cancer	0.00029	0.00612	CcSEcCtD
Methazolamide—Anaphylactic shock—Fluorouracil—colon cancer	0.000288	0.00607	CcSEcCtD
Methazolamide—Anorexia—Irinotecan—colon cancer	0.000287	0.00604	CcSEcCtD
Methazolamide—CYP2C9—digestive system—colon cancer	0.000283	0.0129	CbGeAlD
Methazolamide—Paraesthesia—Vincristine—colon cancer	0.000277	0.00584	CcSEcCtD
Methazolamide—CA5B—Metabolism—CA7—colon cancer	0.000275	0.00222	CbGpPWpGaD
Methazolamide—Anorexia—Fluorouracil—colon cancer	0.000274	0.00578	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000274	0.00578	CcSEcCtD
Methazolamide—CYP2C19—liver—colon cancer	0.000272	0.0124	CbGeAlD
Methazolamide—CYP2E1—lymphoid tissue—colon cancer	0.000271	0.0124	CbGeAlD
Methazolamide—Paraesthesia—Irinotecan—colon cancer	0.00027	0.00569	CcSEcCtD
Methazolamide—Decreased appetite—Vincristine—colon cancer	0.000268	0.00565	CcSEcCtD
Methazolamide—CYP2E1—digestive system—colon cancer	0.000268	0.0123	CbGeAlD
Methazolamide—Erythema multiforme—Capecitabine—colon cancer	0.000268	0.00564	CcSEcCtD
Methazolamide—Somnolence—Irinotecan—colon cancer	0.000267	0.00563	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Vincristine—colon cancer	0.000267	0.00561	CcSEcCtD
Methazolamide—Fatigue—Vincristine—colon cancer	0.000266	0.00561	CcSEcCtD
Methazolamide—Dyspepsia—Irinotecan—colon cancer	0.000265	0.00558	CcSEcCtD
Methazolamide—Tinnitus—Capecitabine—colon cancer	0.000264	0.00556	CcSEcCtD
Methazolamide—CYP3A4—renal system—colon cancer	0.000263	0.012	CbGeAlD
Methazolamide—Decreased appetite—Irinotecan—colon cancer	0.000261	0.00551	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Irinotecan—colon cancer	0.00026	0.00547	CcSEcCtD
Methazolamide—Fatigue—Irinotecan—colon cancer	0.000259	0.00546	CcSEcCtD
Methazolamide—CYP2D6—renal system—colon cancer	0.000259	0.0118	CbGeAlD
Methazolamide—Paraesthesia—Fluorouracil—colon cancer	0.000259	0.00545	CcSEcCtD
Methazolamide—Somnolence—Fluorouracil—colon cancer	0.000256	0.00539	CcSEcCtD
Methazolamide—CA12—Metabolism—CA7—colon cancer	0.000254	0.00206	CbGpPWpGaD
Methazolamide—Dyspepsia—Fluorouracil—colon cancer	0.000253	0.00534	CcSEcCtD
Methazolamide—Decreased appetite—Fluorouracil—colon cancer	0.00025	0.00527	CcSEcCtD
Methazolamide—Pancytopenia—Methotrexate—colon cancer	0.00025	0.00527	CcSEcCtD
Methazolamide—CA2—liver—colon cancer	0.000249	0.0114	CbGeAlD
Methazolamide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000249	0.00524	CcSEcCtD
Methazolamide—Feeling abnormal—Irinotecan—colon cancer	0.000248	0.00522	CcSEcCtD
Methazolamide—Body temperature increased—Vincristine—colon cancer	0.000244	0.00514	CcSEcCtD
Methazolamide—Dysgeusia—Capecitabine—colon cancer	0.000241	0.00509	CcSEcCtD
Methazolamide—Photosensitivity reaction—Methotrexate—colon cancer	0.00024	0.00507	CcSEcCtD
Methazolamide—Body temperature increased—Irinotecan—colon cancer	0.000238	0.00501	CcSEcCtD
Methazolamide—Feeling abnormal—Fluorouracil—colon cancer	0.000237	0.005	CcSEcCtD
Methazolamide—Drowsiness—Methotrexate—colon cancer	0.000235	0.00495	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000233	0.00491	CcSEcCtD
Methazolamide—CA4—lymph node—colon cancer	0.00023	0.0105	CbGeAlD
Methazolamide—Ill-defined disorder—Capecitabine—colon cancer	0.000229	0.00482	CcSEcCtD
Methazolamide—Urticaria—Fluorouracil—colon cancer	0.000229	0.00482	CcSEcCtD
Methazolamide—Body temperature increased—Fluorouracil—colon cancer	0.000228	0.0048	CcSEcCtD
Methazolamide—Haematuria—Methotrexate—colon cancer	0.000224	0.00472	CcSEcCtD
Methazolamide—Malaise—Capecitabine—colon cancer	0.000222	0.00468	CcSEcCtD
Methazolamide—Vertigo—Capecitabine—colon cancer	0.000222	0.00467	CcSEcCtD
Methazolamide—Asthenia—Vincristine—colon cancer	0.000221	0.00467	CcSEcCtD
Methazolamide—Leukopenia—Capecitabine—colon cancer	0.000221	0.00465	CcSEcCtD
Methazolamide—Agranulocytosis—Methotrexate—colon cancer	0.000219	0.00462	CcSEcCtD
Methazolamide—CYP3A4—digestive system—colon cancer	0.000216	0.00987	CbGeAlD
Methazolamide—Asthenia—Irinotecan—colon cancer	0.000216	0.00454	CcSEcCtD
Methazolamide—CYP2D6—digestive system—colon cancer	0.000212	0.00971	CbGeAlD
Methazolamide—Diarrhoea—Vincristine—colon cancer	0.000211	0.00445	CcSEcCtD
Methazolamide—CYP2C9—liver—colon cancer	0.000211	0.00964	CbGeAlD
Methazolamide—CYP3A4—Metapathway biotransformation—CHST4—colon cancer	0.00021	0.0017	CbGpPWpGaD
Methazolamide—CYP2E1—Metapathway biotransformation—CHST5—colon cancer	0.000208	0.00168	CbGpPWpGaD
Methazolamide—Discomfort—Capecitabine—colon cancer	0.000207	0.00437	CcSEcCtD
Methazolamide—Diarrhoea—Irinotecan—colon cancer	0.000206	0.00433	CcSEcCtD
Methazolamide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000204	0.00165	CbGpPWpGaD
Methazolamide—CA4—Metabolism—CA7—colon cancer	0.000203	0.00164	CbGpPWpGaD
Methazolamide—Confusional state—Capecitabine—colon cancer	0.000203	0.00427	CcSEcCtD
Methazolamide—CYP2E1—liver—colon cancer	0.0002	0.00913	CbGeAlD
Methazolamide—Erythema multiforme—Methotrexate—colon cancer	0.000199	0.0042	CcSEcCtD
Methazolamide—Diarrhoea—Fluorouracil—colon cancer	0.000197	0.00415	CcSEcCtD
Methazolamide—Tinnitus—Methotrexate—colon cancer	0.000197	0.00414	CcSEcCtD
Methazolamide—Vomiting—Vincristine—colon cancer	0.000196	0.00414	CcSEcCtD
Methazolamide—Rash—Vincristine—colon cancer	0.000195	0.0041	CcSEcCtD
Methazolamide—CA2—Metabolism—CA7—colon cancer	0.000195	0.00157	CbGpPWpGaD
Methazolamide—Dermatitis—Vincristine—colon cancer	0.000194	0.0041	CcSEcCtD
Methazolamide—Headache—Vincristine—colon cancer	0.000193	0.00407	CcSEcCtD
Methazolamide—Anorexia—Capecitabine—colon cancer	0.000192	0.00404	CcSEcCtD
Methazolamide—Vomiting—Irinotecan—colon cancer	0.000191	0.00403	CcSEcCtD
Methazolamide—CA2—lymph node—colon cancer	0.000191	0.00873	CbGeAlD
Methazolamide—Rash—Irinotecan—colon cancer	0.00019	0.00399	CcSEcCtD
Methazolamide—Dermatitis—Irinotecan—colon cancer	0.000189	0.00399	CcSEcCtD
Methazolamide—Headache—Irinotecan—colon cancer	0.000188	0.00397	CcSEcCtD
Methazolamide—CA1—Metabolism—CA7—colon cancer	0.000187	0.00151	CbGpPWpGaD
Methazolamide—Nausea—Vincristine—colon cancer	0.000183	0.00386	CcSEcCtD
Methazolamide—Vomiting—Fluorouracil—colon cancer	0.000183	0.00386	CcSEcCtD
Methazolamide—CA14—Metabolism—ODC1—colon cancer	0.000183	0.00148	CbGpPWpGaD
Methazolamide—CA14—Metabolism—CHST5—colon cancer	0.000183	0.00148	CbGpPWpGaD
Methazolamide—Rash—Fluorouracil—colon cancer	0.000182	0.00382	CcSEcCtD
Methazolamide—Dermatitis—Fluorouracil—colon cancer	0.000181	0.00382	CcSEcCtD
Methazolamide—Paraesthesia—Capecitabine—colon cancer	0.000181	0.00381	CcSEcCtD
Methazolamide—Headache—Fluorouracil—colon cancer	0.00018	0.0038	CcSEcCtD
Methazolamide—Dysgeusia—Methotrexate—colon cancer	0.00018	0.00379	CcSEcCtD
Methazolamide—Nausea—Irinotecan—colon cancer	0.000179	0.00376	CcSEcCtD
Methazolamide—CA5A—Metabolism—ODC1—colon cancer	0.000178	0.00144	CbGpPWpGaD
Methazolamide—CA6—Metabolism—CHST5—colon cancer	0.000178	0.00144	CbGpPWpGaD
Methazolamide—CA6—Metabolism—ODC1—colon cancer	0.000178	0.00144	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—CHST5—colon cancer	0.000178	0.00144	CbGpPWpGaD
Methazolamide—Dyspepsia—Capecitabine—colon cancer	0.000177	0.00373	CcSEcCtD
Methazolamide—Decreased appetite—Capecitabine—colon cancer	0.000175	0.00369	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Capecitabine—colon cancer	0.000174	0.00366	CcSEcCtD
Methazolamide—Fatigue—Capecitabine—colon cancer	0.000173	0.00365	CcSEcCtD
Methazolamide—Nausea—Fluorouracil—colon cancer	0.000171	0.0036	CcSEcCtD
Methazolamide—Ill-defined disorder—Methotrexate—colon cancer	0.00017	0.00359	CcSEcCtD
Methazolamide—CA1—C-MYB transcription factor network—PTGS2—colon cancer	0.00017	0.00137	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—CHST5—colon cancer	0.000166	0.00135	CbGpPWpGaD
Methazolamide—CA7—Metabolism—ODC1—colon cancer	0.000166	0.00135	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—ODC1—colon cancer	0.000166	0.00135	CbGpPWpGaD
Methazolamide—CA7—Metabolism—CHST5—colon cancer	0.000166	0.00135	CbGpPWpGaD
Methazolamide—Feeling abnormal—Capecitabine—colon cancer	0.000166	0.00349	CcSEcCtD
Methazolamide—Malaise—Methotrexate—colon cancer	0.000166	0.00349	CcSEcCtD
Methazolamide—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000165	0.00134	CbGpPWpGaD
Methazolamide—Vertigo—Methotrexate—colon cancer	0.000165	0.00347	CcSEcCtD
Methazolamide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000165	0.00133	CbGpPWpGaD
Methazolamide—Leukopenia—Methotrexate—colon cancer	0.000164	0.00346	CcSEcCtD
Methazolamide—CA9—Metabolism—CA7—colon cancer	0.000164	0.00133	CbGpPWpGaD
Methazolamide—CYP3A4—liver—colon cancer	0.000161	0.00735	CbGeAlD
Methazolamide—CYP2C19—Metapathway biotransformation—CHST5—colon cancer	0.00016	0.0013	CbGpPWpGaD
Methazolamide—Urticaria—Capecitabine—colon cancer	0.00016	0.00337	CcSEcCtD
Methazolamide—Body temperature increased—Capecitabine—colon cancer	0.000159	0.00335	CcSEcCtD
Methazolamide—Convulsion—Methotrexate—colon cancer	0.000159	0.00335	CcSEcCtD
Methazolamide—CYP2D6—liver—colon cancer	0.000158	0.00723	CbGeAlD
Methazolamide—Discomfort—Methotrexate—colon cancer	0.000154	0.00325	CcSEcCtD
Methazolamide—CA12—Metabolism—ODC1—colon cancer	0.000154	0.00125	CbGpPWpGaD
Methazolamide—CA12—Metabolism—CHST5—colon cancer	0.000154	0.00125	CbGpPWpGaD
Methazolamide—CA1—C-MYB transcription factor network—CCND1—colon cancer	0.000153	0.00124	CbGpPWpGaD
Methazolamide—Confusional state—Methotrexate—colon cancer	0.000151	0.00318	CcSEcCtD
Methazolamide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.00015	0.00122	CbGpPWpGaD
Methazolamide—CA9—HIF-1-alpha transcription factor network—EP300—colon cancer	0.00015	0.00122	CbGpPWpGaD
Methazolamide—Anaphylactic shock—Methotrexate—colon cancer	0.00015	0.00316	CcSEcCtD
Methazolamide—CA1—C-MYB transcription factor network—CDKN1A—colon cancer	0.000148	0.0012	CbGpPWpGaD
Methazolamide—CYP2D6—Metapathway biotransformation—CHST5—colon cancer	0.000148	0.00119	CbGpPWpGaD
Methazolamide—CYP2C9—Metapathway biotransformation—CHST5—colon cancer	0.000146	0.00118	CbGpPWpGaD
Methazolamide—Asthenia—Capecitabine—colon cancer	0.000144	0.00304	CcSEcCtD
Methazolamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000143	0.00116	CbGpPWpGaD
Methazolamide—Anorexia—Methotrexate—colon cancer	0.000143	0.00301	CcSEcCtD
Methazolamide—CA9—HIF-1-alpha transcription factor network—VEGFA—colon cancer	0.000142	0.00115	CbGpPWpGaD
Methazolamide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000142	0.00115	CbGpPWpGaD
Methazolamide—CA1—C-MYB transcription factor network—EP300—colon cancer	0.000141	0.00114	CbGpPWpGaD
Methazolamide—CYP3A4—Irinotecan Pathway—APC—colon cancer	0.000139	0.00112	CbGpPWpGaD
Methazolamide—Diarrhoea—Capecitabine—colon cancer	0.000138	0.0029	CcSEcCtD
Methazolamide—Paraesthesia—Methotrexate—colon cancer	0.000135	0.00283	CcSEcCtD
Methazolamide—Somnolence—Methotrexate—colon cancer	0.000133	0.00281	CcSEcCtD
Methazolamide—CA1—C-MYB transcription factor network—NRAS—colon cancer	0.000132	0.00107	CbGpPWpGaD
Methazolamide—Dyspepsia—Methotrexate—colon cancer	0.000132	0.00278	CcSEcCtD
Methazolamide—Decreased appetite—Methotrexate—colon cancer	0.00013	0.00274	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Methotrexate—colon cancer	0.000129	0.00272	CcSEcCtD
Methazolamide—Fatigue—Methotrexate—colon cancer	0.000129	0.00272	CcSEcCtD
Methazolamide—Vomiting—Capecitabine—colon cancer	0.000128	0.0027	CcSEcCtD
Methazolamide—Rash—Capecitabine—colon cancer	0.000127	0.00267	CcSEcCtD
Methazolamide—Dermatitis—Capecitabine—colon cancer	0.000127	0.00267	CcSEcCtD
Methazolamide—Headache—Capecitabine—colon cancer	0.000126	0.00266	CcSEcCtD
Methazolamide—Feeling abnormal—Methotrexate—colon cancer	0.000123	0.0026	CcSEcCtD
Methazolamide—CA4—Metabolism—CHST5—colon cancer	0.000123	0.000995	CbGpPWpGaD
Methazolamide—CA4—Metabolism—ODC1—colon cancer	0.000123	0.000995	CbGpPWpGaD
Methazolamide—CA1—C-MYB transcription factor network—MYC—colon cancer	0.000123	0.000995	CbGpPWpGaD
Methazolamide—Nausea—Capecitabine—colon cancer	0.00012	0.00252	CcSEcCtD
Methazolamide—Urticaria—Methotrexate—colon cancer	0.000119	0.00251	CcSEcCtD
Methazolamide—Body temperature increased—Methotrexate—colon cancer	0.000118	0.00249	CcSEcCtD
Methazolamide—CA2—Metabolism—ODC1—colon cancer	0.000118	0.000954	CbGpPWpGaD
Methazolamide—CA2—Metabolism—CHST5—colon cancer	0.000118	0.000954	CbGpPWpGaD
Methazolamide—CA1—C-MYB transcription factor network—KRAS—colon cancer	0.000114	0.000919	CbGpPWpGaD
Methazolamide—CA1—Metabolism—ODC1—colon cancer	0.000113	0.000915	CbGpPWpGaD
Methazolamide—CA1—Metabolism—CHST5—colon cancer	0.000113	0.000915	CbGpPWpGaD
Methazolamide—Asthenia—Methotrexate—colon cancer	0.000107	0.00226	CcSEcCtD
Methazolamide—Diarrhoea—Methotrexate—colon cancer	0.000102	0.00216	CcSEcCtD
Methazolamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	9.97e-05	0.000807	CbGpPWpGaD
Methazolamide—CA9—Metabolism—ODC1—colon cancer	9.93e-05	0.000804	CbGpPWpGaD
Methazolamide—CA9—Metabolism—CHST5—colon cancer	9.93e-05	0.000804	CbGpPWpGaD
Methazolamide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	9.92e-05	0.000803	CbGpPWpGaD
Methazolamide—CA1—C-MYB transcription factor network—HRAS—colon cancer	9.65e-05	0.000781	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	9.64e-05	0.000781	CbGpPWpGaD
Methazolamide—Vomiting—Methotrexate—colon cancer	9.52e-05	0.00201	CcSEcCtD
Methazolamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	9.45e-05	0.000765	CbGpPWpGaD
Methazolamide—Rash—Methotrexate—colon cancer	9.44e-05	0.00199	CcSEcCtD
Methazolamide—Dermatitis—Methotrexate—colon cancer	9.44e-05	0.00199	CcSEcCtD
Methazolamide—Headache—Methotrexate—colon cancer	9.38e-05	0.00198	CcSEcCtD
Methazolamide—CA9—HIF-1-alpha transcription factor network—AKT1—colon cancer	9.09e-05	0.000735	CbGpPWpGaD
Methazolamide—Nausea—Methotrexate—colon cancer	8.9e-05	0.00187	CcSEcCtD
Methazolamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	6.58e-05	0.000532	CbGpPWpGaD
Methazolamide—CYP2C19—Arachidonic acid metabolism—PTGS2—colon cancer	6.32e-05	0.000511	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CA7—colon cancer	5.95e-05	0.000482	CbGpPWpGaD
Methazolamide—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	5.76e-05	0.000466	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—CDKN1A—colon cancer	5.21e-05	0.000422	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—EP300—colon cancer	4.96e-05	0.000401	CbGpPWpGaD
Methazolamide—CA14—Metabolism—ABCB1—colon cancer	4.83e-05	0.000391	CbGpPWpGaD
Methazolamide—CA14—Metabolism—TYMS—colon cancer	4.75e-05	0.000384	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—ABCB1—colon cancer	4.71e-05	0.000381	CbGpPWpGaD
Methazolamide—CA6—Metabolism—ABCB1—colon cancer	4.71e-05	0.000381	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—VEGFA—colon cancer	4.7e-05	0.00038	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—TYMS—colon cancer	4.63e-05	0.000374	CbGpPWpGaD
Methazolamide—CA6—Metabolism—TYMS—colon cancer	4.63e-05	0.000374	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CA7—colon cancer	4.59e-05	0.000372	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—ABCB1—colon cancer	4.4e-05	0.000356	CbGpPWpGaD
Methazolamide—CA7—Metabolism—ABCB1—colon cancer	4.4e-05	0.000356	CbGpPWpGaD
Methazolamide—CA7—Metabolism—TYMS—colon cancer	4.32e-05	0.00035	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—TYMS—colon cancer	4.32e-05	0.00035	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CA7—colon cancer	4.22e-05	0.000342	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CA7—colon cancer	4.19e-05	0.000339	CbGpPWpGaD
Methazolamide—CA12—Metabolism—ABCB1—colon cancer	4.07e-05	0.00033	CbGpPWpGaD
Methazolamide—CA12—Metabolism—TYMS—colon cancer	4e-05	0.000324	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ODC1—colon cancer	3.6e-05	0.000292	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CHST5—colon cancer	3.6e-05	0.000292	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—TP53—colon cancer	3.55e-05	0.000287	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PPARG—colon cancer	3.36e-05	0.000272	CbGpPWpGaD
Methazolamide—SLC22A6—Transmembrane transport of small molecules—ABCB1—colon cancer	3.36e-05	0.000272	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PPARG—colon cancer	3.28e-05	0.000265	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PPARG—colon cancer	3.28e-05	0.000265	CbGpPWpGaD
Methazolamide—CA4—Metabolism—ABCB1—colon cancer	3.25e-05	0.000263	CbGpPWpGaD
Methazolamide—CA4—Metabolism—TYMS—colon cancer	3.19e-05	0.000258	CbGpPWpGaD
Methazolamide—CA2—Metabolism—ABCB1—colon cancer	3.11e-05	0.000252	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PPARG—colon cancer	3.06e-05	0.000248	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PPARG—colon cancer	3.06e-05	0.000248	CbGpPWpGaD
Methazolamide—CA2—Metabolism—TYMS—colon cancer	3.06e-05	0.000248	CbGpPWpGaD
Methazolamide—CA1—Metabolism—ABCB1—colon cancer	2.99e-05	0.000242	CbGpPWpGaD
Methazolamide—CA1—Metabolism—TYMS—colon cancer	2.93e-05	0.000237	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PPARG—colon cancer	2.83e-05	0.000229	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CHST5—colon cancer	2.78e-05	0.000225	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ODC1—colon cancer	2.78e-05	0.000225	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CA7—colon cancer	2.76e-05	0.000223	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PTGS2—colon cancer	2.65e-05	0.000214	CbGpPWpGaD
Methazolamide—CA9—Metabolism—ABCB1—colon cancer	2.63e-05	0.000212	CbGpPWpGaD
Methazolamide—CA9—Metabolism—TYMS—colon cancer	2.58e-05	0.000209	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PTGS2—colon cancer	2.58e-05	0.000209	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PTGS2—colon cancer	2.58e-05	0.000209	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ODC1—colon cancer	2.56e-05	0.000207	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CHST5—colon cancer	2.56e-05	0.000207	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ODC1—colon cancer	2.54e-05	0.000205	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CHST5—colon cancer	2.54e-05	0.000205	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PTGS2—colon cancer	2.41e-05	0.000195	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PTGS2—colon cancer	2.41e-05	0.000195	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PPARG—colon cancer	2.26e-05	0.000183	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PTGS2—colon cancer	2.23e-05	0.00018	CbGpPWpGaD
Methazolamide—CA14—Metabolism—EP300—colon cancer	2.2e-05	0.000178	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PPARG—colon cancer	2.17e-05	0.000175	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—EP300—colon cancer	2.14e-05	0.000174	CbGpPWpGaD
Methazolamide—CA6—Metabolism—EP300—colon cancer	2.14e-05	0.000174	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PPARG—colon cancer	2.08e-05	0.000168	CbGpPWpGaD
Methazolamide—CA7—Metabolism—EP300—colon cancer	2e-05	0.000162	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—EP300—colon cancer	2e-05	0.000162	CbGpPWpGaD
Methazolamide—CA12—Metabolism—EP300—colon cancer	1.85e-05	0.00015	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PPARG—colon cancer	1.83e-05	0.000148	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PTGS2—colon cancer	1.78e-05	0.000144	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PTGS2—colon cancer	1.7e-05	0.000138	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CHST5—colon cancer	1.67e-05	0.000135	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ODC1—colon cancer	1.67e-05	0.000135	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PTGS2—colon cancer	1.63e-05	0.000132	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PIK3CA—colon cancer	1.63e-05	0.000132	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PIK3CA—colon cancer	1.59e-05	0.000128	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PIK3CA—colon cancer	1.59e-05	0.000128	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PIK3CA—colon cancer	1.48e-05	0.00012	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PIK3CA—colon cancer	1.48e-05	0.00012	CbGpPWpGaD
Methazolamide—CA4—Metabolism—EP300—colon cancer	1.48e-05	0.00012	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PTGS2—colon cancer	1.44e-05	0.000116	CbGpPWpGaD
Methazolamide—CA2—Metabolism—EP300—colon cancer	1.42e-05	0.000115	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PIK3CA—colon cancer	1.37e-05	0.000111	CbGpPWpGaD
Methazolamide—CA1—Metabolism—EP300—colon cancer	1.36e-05	0.00011	CbGpPWpGaD
Methazolamide—CA14—Metabolism—AKT1—colon cancer	1.33e-05	0.000108	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—AKT1—colon cancer	1.3e-05	0.000105	CbGpPWpGaD
Methazolamide—CA6—Metabolism—AKT1—colon cancer	1.3e-05	0.000105	CbGpPWpGaD
Methazolamide—CA7—Metabolism—AKT1—colon cancer	1.21e-05	9.79e-05	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—AKT1—colon cancer	1.21e-05	9.79e-05	CbGpPWpGaD
Methazolamide—CA9—Metabolism—EP300—colon cancer	1.19e-05	9.67e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.15e-05	9.29e-05	CbGpPWpGaD
Methazolamide—CA12—Metabolism—AKT1—colon cancer	1.12e-05	9.07e-05	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PIK3CA—colon cancer	1.09e-05	8.85e-05	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PIK3CA—colon cancer	1.05e-05	8.49e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.05e-05	8.47e-05	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PIK3CA—colon cancer	1.01e-05	8.14e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ABCB1—colon cancer	9.53e-06	7.71e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—TYMS—colon cancer	9.35e-06	7.57e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	9.03e-06	7.31e-05	CbGpPWpGaD
Methazolamide—CA4—Metabolism—AKT1—colon cancer	8.94e-06	7.23e-05	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PIK3CA—colon cancer	8.84e-06	7.15e-05	CbGpPWpGaD
Methazolamide—CA2—Metabolism—AKT1—colon cancer	8.57e-06	6.93e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	8.23e-06	6.67e-05	CbGpPWpGaD
Methazolamide—CA1—Metabolism—AKT1—colon cancer	8.21e-06	6.65e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—colon cancer	7.51e-06	6.08e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ABCB1—colon cancer	7.35e-06	5.95e-05	CbGpPWpGaD
Methazolamide—CA9—Metabolism—AKT1—colon cancer	7.22e-06	5.84e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—TYMS—colon cancer	7.22e-06	5.84e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	6.85e-06	5.54e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ABCB1—colon cancer	6.76e-06	5.47e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ABCB1—colon cancer	6.7e-06	5.42e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—TYMS—colon cancer	6.64e-06	5.37e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PPARG—colon cancer	6.63e-06	5.36e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—TYMS—colon cancer	6.58e-06	5.33e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.56e-06	4.5e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PTGS2—colon cancer	5.21e-06	4.22e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PPARG—colon cancer	5.11e-06	4.14e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.07e-06	4.1e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PPARG—colon cancer	4.7e-06	3.81e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PPARG—colon cancer	4.66e-06	3.77e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ABCB1—colon cancer	4.42e-06	3.58e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—TYMS—colon cancer	4.34e-06	3.51e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—EP300—colon cancer	4.34e-06	3.51e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PTGS2—colon cancer	4.02e-06	3.26e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PTGS2—colon cancer	3.7e-06	2.99e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PTGS2—colon cancer	3.67e-06	2.97e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—EP300—colon cancer	3.35e-06	2.71e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PIK3CA—colon cancer	3.21e-06	2.6e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—EP300—colon cancer	3.08e-06	2.49e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PPARG—colon cancer	3.07e-06	2.49e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—EP300—colon cancer	3.05e-06	2.47e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—AKT1—colon cancer	2.62e-06	2.12e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PIK3CA—colon cancer	2.47e-06	2e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PTGS2—colon cancer	2.42e-06	1.96e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PIK3CA—colon cancer	2.28e-06	1.84e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PIK3CA—colon cancer	2.26e-06	1.83e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—AKT1—colon cancer	2.02e-06	1.64e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—EP300—colon cancer	2.01e-06	1.63e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—AKT1—colon cancer	1.86e-06	1.5e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—AKT1—colon cancer	1.84e-06	1.49e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PIK3CA—colon cancer	1.49e-06	1.2e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—AKT1—colon cancer	1.22e-06	9.84e-06	CbGpPWpGaD
